Stockreport

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics, Inc.  (ONCT) 
Last oncternal therapeutics, inc. earnings: 8/8 04:01 pm Check Earnings Report
PDF SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of nov [Read more]